ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D.,
Acorda's President and CEO, will present at the Stifel 2018 Healthcare
Conference on Tuesday, November 13 at 2:00pm EST. A live audio webcast
of the presentation can be accessed under “Investor Events” in the
Investor section of the Acorda website at www.acorda.com,
or you may use the link:
http://wsw.com/webcast/stifel14/acor/
About Acorda Therapeutics
Acorda Therapeutics develops
therapies to restore function and improve the lives of people with
neurological disorders. INBRIJA™ (levodopa inhalation powder), an
investigational inhaled formulation of levodopa for symptoms of OFF
periods for people with Parkinson’s on a carbidopa/levodopa regimen, is
under FDA review with a PDUFA date of January 5, 2019. INBRIJA utilizes
Acorda’s innovative ARCUS® pulmonary delivery system, a technology
platform designed to deliver medication through inhalation. Acorda also
markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
Forward-Looking Statement
This press release includes
forward-looking statements. All statements, other than statements of
historical facts, regarding management's expectations, beliefs, goals,
plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause
actual results to differ materially, including: the ability to realize
the benefits anticipated from acquisitions, among other reasons because
acquired development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the risks
specifically relevant to acquired programs generally improves over time;
we may need to raise additional funds to finance our operations and may
not be able to do so on acceptable terms; increasing competition and
accompanying loss of revenues in the U.S. from generic versions of
Ampyra (dalfampridine) following our loss of patent exclusivity; the
risk of unfavorable results from future studies of Inbrija (levodopa
inhalation powder) or from our other research and development programs,
or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully
market Inbrija or any other products under development; risks associated
with complex, regulated manufacturing processes for pharmaceuticals,
which could affect whether we have sufficient commercial supply of
Inbrija to meet market demand, if it receives regulatory approval; third
party payers (including governmental agencies) may not reimburse for the
use of Ampyra, Inbrija or our other products at acceptable rates or at
all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the occurrence of adverse safety events
with our products; the outcome (by judgment or settlement) and costs of
legal, administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective, representative
or class action litigation; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and failure to comply
with regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181108005062/en/
Acorda Therapeutics, Inc.
Felicia Vonella, 914-326-5146
fvonella@acorda.com
Source: Acorda Therapeutics, Inc.